Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma

Proteasome inhibitors in cancer therapy

(2017) Elisabet E. Manasanch et al.   Nature Reviews Clinical Oncology

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

(2016) P. Sonneveld et al.   BLOOD

Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs

(2016) Takumi Ito et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Overexpression of c-myc is associated with adverse clinical features and worse overall survival in multiple myeloma

(2016) Agoston Gyula Szabo et al.   LEUKEMIA & LYMPHOMA

Synergistic action of master transcription factors controls epithelial-to-mesenchymal transition

(2016) Hongyuan Chang et al.   NUCLEIC ACIDS RESEARCH

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer

(2016) Kanak Raina et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

(2016) Sandy Amorim et al.   Lancet Haematology

Cereblon binding molecules in multiple myeloma

(2015) K.M. Kortüm et al.   BLOOD REVIEWS

A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma

(2015) Johanna C. Bendell et al.   CANCER

Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy

(2015) Elias E. Stratikopoulos et al.   CANCER CELL

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

(2015) Jing Lu et al.   CHEMISTRY & BIOLOGY

The PtdIns3-phosphatase MTMR3 interacts with mTORC1 and suppresses its activity

(2015) Feike Hao et al.   FEBS LETTERS

Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study

(2015) A. Gunther et al.   HAEMATOLOGICA

The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma

(2015) Bingzong Li et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phthalimide conjugation as a strategy for in vivo target protein degradation

(2015) G. E. Winter et al.   SCIENCE

Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study

(2015) A. Gunther et al.   HAEMATOLOGICA

mLST8 Promotes mTOR-Mediated Tumor Progression

(2015) Kyoko Kakumoto et al.   PLoS One

The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

(2014) A. Spencer et al.   BLOOD

The impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy

(2014) Naohiro Sekiguchi et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma

(2014) M Affer et al.   LEUKEMIA

Chromosome 8q24.1/c-MYCabnormality: a marker for high-risk myeloma

(2014) Isabella C. Glitza et al.   LEUKEMIA & LYMPHOMA

Bromodomain and Extraterminal Domain Inhibitors (BETi) for Cancer Therapy: Chemical Modulation of Chromatin Structure

(2014) J. Qi   Cold Spring Harbor Perspectives in Biology

Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients

(2014) B A Walker et al.   Blood Cancer Journal

Impact of MYC on malignant behavior

(2014) G. Ott   Hematology-American Society of Hematology Education Program

Targeting PI3K/mTOR Signaling in Cancer

(2014) Alexandre Arcaro   Frontiers in Oncology

Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1

(2013) Teresa S. Hawley et al.   AMERICAN JOURNAL OF HEMATOLOGY

Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation

(2013) J. Lu et al.   BLOOD

NEK2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers

(2013) Wen Zhou et al.   CANCER CELL

Phospho Switch Triggers Brd4 Chromatin Binding and Activator Recruitment for Gene-Specific Targeting

(2013) Shwu-Yuan Wu et al.   MOLECULAR CELL

BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models

(2013) Anastasia Wyce et al.   PLoS One

Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers

(2013) M. Pourdehnad et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Role of PRAS40 in Akt and mTOR signaling in health and disease

(2012) Claudia Wiza et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

(2012) D. J. Kuhn et al.   BLOOD

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Proteasome inhibition leads to dephosphorylation and downregulation of protein expression of members of the Akt/mTOR pathway in MCL

(2012) G Hutter et al.   LEUKEMIA

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

(2011) Y. X. Zhu et al.   BLOOD

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin

(2010) Gabriele Buda et al.   ANNALS OF HEMATOLOGY

Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide

(2010) Chad C. Bjorklund et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Selective inhibition of BET bromodomains

(2010) Panagis Filippakopoulos et al.   NATURE

Identification of a Primary Target of Thalidomide Teratogenicity

(2010) T. Ito et al.   SCIENCE

Pim kinase-dependent inhibition of c-Myc degradation

(2008) Y Zhang et al.   ONCOGENE

Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1

(2008) J. Zhu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA